Cargando…

A randomised controlled trial to evaluate a medication monitoring system for TB treatment

BACKGROUND : Adherence to TB treatment and therefore treatment success could be improved using digital adherence technology. OBJECTIVE : To evaluate the effectiveness of a medication event reminder monitor system (MERM) on treatment success and treatment adherence in patients with drug-susceptible p...

Descripción completa

Detalles Bibliográficos
Autores principales: Acosta, J., Flores, P., Alarcón, M., Grande-Ortiz, M., Moreno-Exebio, L., Puyen, Z. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Union Against Tuberculosis and Lung Disease 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734191/
https://www.ncbi.nlm.nih.gov/pubmed/34969428
http://dx.doi.org/10.5588/ijtld.21.0373
Descripción
Sumario:BACKGROUND : Adherence to TB treatment and therefore treatment success could be improved using digital adherence technology. OBJECTIVE : To evaluate the effectiveness of a medication event reminder monitor system (MERM) on treatment success and treatment adherence in patients with drug-susceptible pulmonary TB in Perú. METHODS : This was an experimental, randomised, open-label, controlled study conducted among patients in the second phase of TB treatment. The intervention group received their medications through MERM with the support of a treatment monitor, whereas the control group used the usual strategy. Participants were followed until they completed the 54 doses of the second phase of treatment. RESULTS : The study included 53 patients in each group; four in the intervention group withdrew from the study. Treatment success was significantly more frequent in the MERM group (RR 1.15, 95% CI 1.02–1.30; P = 0.0322). There was no significant difference in the adherence outcomes; however, the percentage of patients who missed at least one dose and patients with more than 10% of total doses missed were lower in the intervention group. CONCLUSION : The use of MERM in the second phase of treatment showed a significant improvement in the treatment success rate in patients with drug-susceptible pulmonary TB.